Survival studies of patients with breast cancer, prostate cancer, pancreatic cancer, bladder cancer, hematological malignancies, and hepatocellular carcinoma have shown that high expression of ZBTB7A is associated with poor prognosis [28–33]. Here, ZBTB7A is linked to hematologic disorder.